A trial of mithramycin in the treatment of advanced malignant disease

Clinical Trial

. 1966 Jun;20(2):256-63.

doi: 10.1038/bjc.1966.32.

Free PMC article

Clinical Trial

I A Sewell et al. Br J Cancer. 1966 Jun.

Free PMC article

. 1966 Jun;20(2):256-63.

doi: 10.1038/bjc.1966.32.

No abstract available

Cited by

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer.
Schweer D, McCorkle JR, Rohr J, Tsodikov OV, Ueland F, Kolesar J. Schweer D, et al. Biomedicines. 2021 Jan 12;9(1):70. doi: 10.3390/biomedicines9010070. Biomedicines. 2021. PMID: 33445667 Free PMC article. Review.
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M, Atay SM, Shukla V, Hong Y, Upham T, Ripley RT, Hong JA, Zhang M, Reardon E, Fetsch P, Miettinen M, Li X, Peer CJ, Sissung T, Figg WD, De Rienzo A, Bueno R, Schrump DS. Rao M, et al. Clin Cancer Res. 2016 Mar 1;22(5):1197-210. doi: 10.1158/1078-0432.CCR-14-3379. Epub 2015 Oct 12. Clin Cancer Res. 2016. PMID: 26459178 Free PMC article.
A clinical trial of mithramycin in the treatment of advanced malignant disease.
Baum M. Baum M. Br J Cancer. 1968 Jun;22(2):176-83. doi: 10.1038/bjc.1968.25. Br J Cancer. 1968. PMID: 4873186 Free PMC article. Clinical Trial. No abstract available.
Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.
Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, Widemann BC, Heller T, Schrump DS, Figg WD. Sissung TM, et al. Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7. Mol Pharmacol. 2019. PMID: 31175181 Free PMC article.